تصفح Pharmacy Research حسب الموضوع "immune-checkpoint inhibitors"
السجلات المعروضة 1 -- 1 من 1
-
Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients
( Frontiers Media S.A. , 2023 , Article)Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes of NSCLC patients with better overall survival. However, 15-40% of the patients still ...